# Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

> **NCT01546571** · PHASE3 · TERMINATED · sponsor: **Polynoma LLC** · enrollment: 504 (actual)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** POL-103A
- **BIOLOGICAL:** POL-103A without API

## Key facts

- **NCT ID:** NCT01546571
- **Lead sponsor:** Polynoma LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-05-01
- **Primary completion:** 2021-04-29
- **Final completion:** 2021-06-30
- **Target enrollment:** 504 (ACTUAL)
- **Why stopped:** After interim analysis the study was halted to redesign a pivotal trial.
- **Last updated:** 2025-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01546571

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01546571, "Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01546571. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*